Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease

BMC Medical Genetics

Table 3 Clinical correlates of adherence to tumor surveillance program

Clinical features	n	Follow-up (+)	Follow-up (-)	p
Gender	36			n.s.
Male	13	5	8
Female	23	9	14
Pre-test clinical status	36			p = 0.02
Asymptomatic		3	14
Symptomatic		11	8
Pre-test depression^†	17			n.s.
Yes		1	3
No		6	7
Pre-test anxiety^‡	17			p = 0.01
Yes		0	7
No		6	4
Offspring	36			n.s.
One or more children		7	9
No children		7	13
Clinical status of offspring^†‡	16			n.s.
Affected		2	3
Unaffected		5	6
Mutation status of offspring^†‡	16			n.s.
Mutation-carrier		5	6
Non mutation-carrier		2	3

Follow-up (+): Patients that continued in the tumor surveillance program five years after genetic testing. Follow-up (-): Patients that had abandoned the tumor surveillance program five years after genetic testing.
^† Score ≥ 10 on Beck's Depression Inventory. Includes individuals that completed the psychological questionnaires (n = 17)
^‡ Score ≥ 8 on Beck's Anxiety Inventory. Includes individuals that completed the psychological questionnaires (n = 17)
^†‡ Includes mutation-carriers who had children (n = 16)

ISSN: 1471-2350